Abstract 3566
Background
CAT is a common complication of cancer with impact on overall prognosis. After 2003 low molecular weight heparin (LMWH) instead of vitamin K antagonists (VKA) became guideline recommended treatment. Direct oral anticoagulant drugs (DOAC) were investigated in CAT only recently. Little data is available concerning incidence and current treatment situation in Germany.
Methods
Data on drugs and coding of diagnosis for all continuously insured members of SHI were available. An anonymized health claims database (2011-2016) of German SHI was used for a retrospective analysis. With a wash out period of one year patients with preexisting conditions were eliminated. According to our definition pts with CAT had a new a cancer diagnosis and a new VTE diagnosis and a prescrition of any type of anticoagulant. Anticoagulant drug type and duration in CAT pts during the next year was analyzed and then classified according to their dominant (> 51 % of time) anticoagulant drug. Any coded bleeding diagnosis was captured as well. The study has descriptive character.
Results
Out of a sample of > 4 million MSHI which is 5,5 % of the German SHI population 322,600 tumor pts and 13,131 (4%) pts with initial VTE diagnosis were identified. 25% of them had no prescription of any anticoagulant. According to the definition 7,313 were CAT. Dominant anticoagulant was LMWH in 58% VKA in 24%, and DOAC in 18%, respectively. During prescription of anticoagulation approx. 20% of all pts with CAT suffered from bleedings with no significant differences between agents (LMWH, DOAC, VKA). The individual LMWH type (approved for secondary prophylaxis or not) and switch of therapy were analyzed as well.
Conclusions
Out of 7,313 pts with CAT more than half received secondary prophylaxis of VTE with LMWH in accordance with the German guideline. VKA (probably suboptimal choice) as well as DOAC (no data publised before 2017) were used in a clinically relevant subset. Bleeding was comparable in different agents of anticoagulation. As compared to available small market research studies our data set offers more reliable information due to its comprehensive character. This has impact on future guidelines and education.
Clinical trial identification
Legal entity responsible for the study
HGC Healthcare Consultants GmbH.
Funding
Aspen Germany GmbH.
Editorial Acknowledgement
Disclosure
A. Kretzschmar: Travel cost compensation: Aspen Pharma. M. May: Research funding: Aspen Pharma GmbH, Germany; Compensation for travel, Employee: HGC. A. Heinken: Employee: Aspen Pharma, Germany. H. Riess: Travel compensation, Honoraria, Advisory board: Aspen Pharma, Bayer Schering, Daiichi Sankyo, Boehringer Ingelheim, Leo-Pharma.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract